SlideShare a Scribd company logo
QUANTITATIVE RISK ASSESSMENT
AND THE CATEGORISATION OF
OCCUPATIONAL EXPOSURE TO
CHEMICAL AGENTS/APIs
1. INTRODUCTION
2. RISK ASSESSMENT
3. CATEGORIZATION
2
INTRODUCTION
INTRODUCTION
The Occupational Exposure Limit (OEL) is defined as the airborne concentration of a
substance (expressed as a weighted average in time for a working day of 8 hours/day
and 40 hours/working week) under which it is believed that nearly all workers may
be repeatedly exposed (day after day, over a working lifetime) without adverse
health effects (ACGIH, 2006; DFG, 2005).
Occupational exposure limits (OELs) are a useful tool to prevent adverse effects on
health when managing chemical substances.
On a European scale…
• Employers are legally obliged to provide a work environment that does not
threaten the health of the workers (Chemical Agent Directive 98/24/EC and
Framework Directive 89/391/EEC).
• Under Directive 89/391/EEC, OELs can be developed nationally, Indicative
Occupational Exposure Limit Values (IOELVs).
4
INTRODUCTION
SOME LIMIT VALUES IN THE WORLD
• TLV ®(1950): Threshold Limit Value
American Conference of Governmental Industrial Hygienists (ACGIH)
• REL®: Recomended Exposure Limits
National Institute for Occupational Safety and Health (NIOSH)
• PEL®: Permissible Exposure Limits
Occupational Safety and Health Administration (OSHA)
• OEL®: Occupational Exposure Limits
Health and Safety Executive (HSE)
• VME®: Valeurs Moyennes d´Exposition
Institute National de la Recherche et la Securité (INRS)
• MAK®: Maximale Arbeitsplatzkoncentrationen
Deustche Forschungsgemeinschaft (DFG)
GESTIS - International limit values for chemical agents
5
6
RISK ASSESSMENT
RISK ASSESSMENT (ECETOC TR No. 101)
What should we do if
there is no regulatory OEL
value?
7
RISK ASSESSMENT(ECETOC TR No. 101)
We calculate the OEL based on:
• Epidemiological studies or
• Toxicological data selecting the point of departure (POD) established by
repeated dosage studies in animals and applying appropriate correction
factors (ECETOC, 2003a) to take uncertainty and variability in the set of data
into account:
➢ NOAEL no-observed-adverse-effect level and
➢ LOAEL lowest-observed-adverse-effect level
8
RISK ASSESSMENT
9
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting
Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
RISK ASSESSMENT (ECETOC TR No. 101)
Relevant points to establish an OEL:
• Repeated dosage studies must last for at least 28 days.
• Toxicokinetic studies can provide information on the extent to which the
manner of exposure, distribution, metabolism and excretion of the substance
in animals are adequate to establish an OEL in humans.
• The criteria to select a NOAEL include the selection of the most relevant
species for man. If several studies are conducted with different species, the
highest NOAEL must be used, but this NOAEL must not exceed the LOAEL in
any of the other studies
10
RISK ASSESSMENT
Correction factors:
11
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational
Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
RISK ASSESSMENT
Correction factors
UFA
12
RISK ASSESSMENT
Correction factors:
• UFH : A value of 10 is normally used for the general population, in the absence of
specific chemical data.
• UFL : 1 (POD=NOAEL), 10 (POD=LOAEL)
• UFS : The purpose of OELs is to protect workers that are exposed throughout
their working life, in animals this is usually compared with a chronic study (e.g.
two (2) years for rats and mice).
13
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits.
J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
RISK ASSESSMENT
UFD: 1-10. Incomplete toxicological data (studies of a single species, there are no
reproduction or development data, etc.)
Toxicokinetic (TK) adjustment:
Example: If an OEL is established from a critical effect in an oral study with a
bioavailability of 10%, bearing in mind that bioavailability for inhalation is 100%:
1.0/0.1 or a factor of 10.
Modification factor (MF): This factor is adjusted for uncertainties not tackled by
the UFs described above (<1 to 10).
14
D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational
Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
RISK ASSESSMENT (ECETOC TR No. 101)
If there is no NOAEL/LOAEL:
• The maximum tolerated dose in long term studies can be used to establish an
OEL. If this is not known, the maximum tolerated dose can be predicted based
on acute oral toxicity (lethal dose in rats) and the octanol-water distribution
coefficient.
Molecules with a molecular mass of <500 and a Kow log of 0–4 are absorbed well
orally or by inhalation.
• Lethal concentrations of four hours of inhalation studies in rats can be
directly used to calculate the OEL.
15
RISK ASSESSMENT (ECETOC TR No. 101)
If there is no NOAEL/LOAEL:
• The use of QSARs to predict the toxicity is not reliable enough, therefore, they
are of limited value when it comes to establishing the OEL. It is better to look
for substances with similar structures and known toxicity (Read-across).
ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/) (NLM, 2004).
• You can resort to the Threshold of Toxicological Concern (TTC), which is
normally used for food contaminants to determine the OEL by the most
conservative method. The first step in applying the TTC concept for a
particular substance is to identify the possible genotoxic effects and/or highly
potent carcinogens. If estimated intake does not exceed 1.5 μg / person / day,
you would not expect the substance to be a safety problem.
16
RISK ASSESSMENT (ECETOC TR No. 101)
At present, there are no procedures to establish the OELs for data-poor
substances.
Data poor substances: Substances that fall under Annex V of REACH (volume of
up to 10 t/year) form part of this category.
One possibility could be to use the derived-no-effect level (DNEL), taking this as
an OEL equivalent.
17
18
Considerations to be taken into account:
• The absorption of a chemical substance is conditioned by:
➢ Physical state: Gas (inhalation), liquid (vapour inhalation, aerosol
droplets, directly through the skin), solid (aerosol inhalation)
➢ Temperature: When handling, during shipment, storage, etc.
➢ Dust of any type can become a hazardous substance when it is
present in airborne concentrations equal to or over 10 mg / m3 of
inhalable dust or 4 mg / m3 of respirable dust.
RISK ASSESSMENT (ECETOC TR No. 101)
19
Considerations to be taken into account:
✓ The substance can also cause harm when:
• being absorbed through the skin;
• being ingested; or
• acting directly on the body at the point
of contact, e.g. the skin.
RISK ASSESSMENT (ECETOC TR No. 101)
20
RESPIRATORY/SKIN/EYE IRRITANT AGENT
Because of its limited solubility in water, the substance may reach:
• The alveoli or
• Be inhaled as critically-sized particles ("respirable dust"),
The OEL must be based on the prevention of:
➢ Damage to the lung epithelium in the short term
➢ COPD, emphysema or pulmonary fibrosis after long-term exposure.
Contact with the skin can cause irritation and contact dermatitis. If a substance has
a high octanol-water partition coefficient and a low skin DL50, e.g. 1000 mg / kg,
the possibility of skin irritation must be considered.
RISK ASSESSMENT
21
RESPIRATORY SENSITISER AGENT
A substance is considered to cause occupational asthma if, on account of exposure in
the workplace:
➢ It provokes a biological change known as a “hypersensitive state” in the
respiratory tracts; and
➢ It provokes a subsequent reaction in those respiratory tracts.
• Substances may not be hazardous in solid form but may indeed by so in fine
powder or dust form which can be inhaled into the lungs.
• Nanoparticles (<100 nanometres) can be more toxic than bigger ones of the same
substance.
• Impurities in a substance can make it more dangerous.
RISK ASSESSMENT
22
SKIN SENSITISER AGENT
Allergic skin contact: Repeated exposure to a relatively low concentration.
There is a class of chemical substances that can cause allergic reactions in the skin
after exposure to sunlight or ultraviolet (UV) light. These chemical products are
known as photosensitisers.
Penetration of the skin can increase in highly humid settings. When temperatures
are high, perspiration can contribute to greater skin absorption.
RISK ASSESSMENT
23
An adjusted OEL (AOEL) can be calculated when worker exposure time is not 8 hours a
day
RISK ASSESSMENT- AOELs
How is the OEL calculated in compounds?
Three possible compound cases are considered:
Synergistic substances: Quite uncommon. These are the most serious cases.
Additive substances: when there are reasons to believe that the effect of the
components are additive and are based on the same effects on health.
Independent substances: when the synergistic or additive effects are not known or
considered unlikely, the constituents can be considered as working independently and
the requisite measures are analysed to attain adequate control separately.
24
RISK ASSESSMENT- COMPOUNDS (ECETOC TR
No. 101)
25
➢ If the total is < 1, exposure to the compound is below the OEL value
➢ If the total is > 1, exposure to the compound is above the OEL value
RISK ASSESSMENT- COMPOUNDS (ECETOC TR
No. 101)
Additive:
26
RISK ASSESSMENT- COMPOUNDS (ECETOC TR
No. 101)
27
✓ Toxicology databases for the work environment
✓ Buscatox
✓ QSAR/READ-ACROSS
✓ Danish QSAR
✓ Toxtree
✓ Vega
RISK ASSESSMENT- DATA BASE
28
CATEGORIZATION
CATEGORIZATION SYSTEMS
Naumann et al., 1996:
• system based on five (5) categories
• range of permissible occupational exposure limits (PEL) that range from 1000 - 5000
μg/m3 in category 1 to those values under 100 ng/m3 in category 5.
Safebridge (SB) proposes, as does the ISPE
• a system based on four (4) categories
• a broader band range than in the previous case.
INSHT (NTP 798)
System based on five (5) categories
29
CATEGORIZATION SYSTEMS - AZIERTA
30
See the table in www.azierta.eu
Once the OEL value has been calculated and the toxicological analysis of the
substance carried out, a categorization of the substance shall be carried out taking
into account the toxicological and pharmacological characteristics as well as the
physicochemical properties of the substance.
In Azierta we are experts in Exposure Limits,
Categorization of APIs and Protocols of Health
Surveillance if you want to know us visit:
Azierta
Or follow us on :
Azierta
@Azierta

More Related Content

What's hot

Extractables and Leachables for Medical Devices
Extractables and Leachables for Medical DevicesExtractables and Leachables for Medical Devices
Extractables and Leachables for Medical Devices
Pine Lake Laboratories
 
Best techniques to control Genotoxities and impact of ICH M7 guideline
Best techniques to control Genotoxities and impact of ICH M7 guidelineBest techniques to control Genotoxities and impact of ICH M7 guideline
Best techniques to control Genotoxities and impact of ICH M7 guideline
Bhaswat Chakraborty
 
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk ManagementICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management
Seetharam Kandarpa ASQ CMQ/OE, CPGP, CQA
 
ICH Guideline – Q9
ICH Guideline – Q9ICH Guideline – Q9
ICH Guideline – Q9
rx_sonali
 
Occupational exposure-limits
Occupational exposure-limitsOccupational exposure-limits
Occupational exposure-limits
Ahmed-Refat Refat
 
Compressed Gas Safety Training by DL&I PA
Compressed Gas Safety Training by DL&I PACompressed Gas Safety Training by DL&I PA
Compressed Gas Safety Training by DL&I PA
Atlantic Training, LLC.
 
Material characterization per ISO 10993-18: When is it needed & how do I sati...
Material characterization per ISO 10993-18: When is it needed & how do I sati...Material characterization per ISO 10993-18: When is it needed & how do I sati...
Material characterization per ISO 10993-18: When is it needed & how do I sati...
UBMCanon
 
Ich guidelines for stability studies 2
Ich guidelines for stability studies 2Ich guidelines for stability studies 2
Ich guidelines for stability studies 2
priyanka odela
 
Cleaning validation
Cleaning validationCleaning validation
Chemical Characterization of Medical Device Catheters
Chemical Characterization of Medical Device CathetersChemical Characterization of Medical Device Catheters
Chemical Characterization of Medical Device Catheters
Pacific BioLabs
 
Setting spec limit for imps
Setting spec limit for impsSetting spec limit for imps
Setting spec limit for imps
ICHAPPS
 
AMIT - QbD, a case study
AMIT - QbD, a case studyAMIT - QbD, a case study
AMIT - QbD, a case studyAmit Mukharya
 
Q3D Guideline For Elemental Impurities
Q3D Guideline For Elemental ImpuritiesQ3D Guideline For Elemental Impurities
Q3D Guideline For Elemental Impurities
Muhamad Abdalkader
 
Nitrosamine Impurities; A Failure, Challenge & Threat
Nitrosamine Impurities; A Failure, Challenge & ThreatNitrosamine Impurities; A Failure, Challenge & Threat
Nitrosamine Impurities; A Failure, Challenge & Threat
Obaid Ali / Roohi B. Obaid
 
Schedule M drugs and Cosmetics_Good manufacturing practices
Schedule M drugs and Cosmetics_Good manufacturing practicesSchedule M drugs and Cosmetics_Good manufacturing practices
Schedule M drugs and Cosmetics_Good manufacturing practices
VETERINARY COLLEGE AND RESEARCH INSTITUTE, ORATHANADU - TANUVAS
 
Extractable and leachables
Extractable and leachablesExtractable and leachables
Extractable and leachables
Saikiran Koyalkar
 
History & Evolution of GMP Regulations
History & Evolution of GMP RegulationsHistory & Evolution of GMP Regulations
History & Evolution of GMP Regulations
GMP EDUCATION : Not for Profit Organization
 
Ich q3 d elemental impurities
Ich q3 d elemental impuritiesIch q3 d elemental impurities
Ich q3 d elemental impurities
santoshnarla
 
Quality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental MonitoringQuality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental Monitoring
GMP EDUCATION : Not for Profit Organization
 
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
Jordi Labs
 

What's hot (20)

Extractables and Leachables for Medical Devices
Extractables and Leachables for Medical DevicesExtractables and Leachables for Medical Devices
Extractables and Leachables for Medical Devices
 
Best techniques to control Genotoxities and impact of ICH M7 guideline
Best techniques to control Genotoxities and impact of ICH M7 guidelineBest techniques to control Genotoxities and impact of ICH M7 guideline
Best techniques to control Genotoxities and impact of ICH M7 guideline
 
ICH Q9 Quality Risk Management
ICH Q9 Quality Risk ManagementICH Q9 Quality Risk Management
ICH Q9 Quality Risk Management
 
ICH Guideline – Q9
ICH Guideline – Q9ICH Guideline – Q9
ICH Guideline – Q9
 
Occupational exposure-limits
Occupational exposure-limitsOccupational exposure-limits
Occupational exposure-limits
 
Compressed Gas Safety Training by DL&I PA
Compressed Gas Safety Training by DL&I PACompressed Gas Safety Training by DL&I PA
Compressed Gas Safety Training by DL&I PA
 
Material characterization per ISO 10993-18: When is it needed & how do I sati...
Material characterization per ISO 10993-18: When is it needed & how do I sati...Material characterization per ISO 10993-18: When is it needed & how do I sati...
Material characterization per ISO 10993-18: When is it needed & how do I sati...
 
Ich guidelines for stability studies 2
Ich guidelines for stability studies 2Ich guidelines for stability studies 2
Ich guidelines for stability studies 2
 
Cleaning validation
Cleaning validationCleaning validation
Cleaning validation
 
Chemical Characterization of Medical Device Catheters
Chemical Characterization of Medical Device CathetersChemical Characterization of Medical Device Catheters
Chemical Characterization of Medical Device Catheters
 
Setting spec limit for imps
Setting spec limit for impsSetting spec limit for imps
Setting spec limit for imps
 
AMIT - QbD, a case study
AMIT - QbD, a case studyAMIT - QbD, a case study
AMIT - QbD, a case study
 
Q3D Guideline For Elemental Impurities
Q3D Guideline For Elemental ImpuritiesQ3D Guideline For Elemental Impurities
Q3D Guideline For Elemental Impurities
 
Nitrosamine Impurities; A Failure, Challenge & Threat
Nitrosamine Impurities; A Failure, Challenge & ThreatNitrosamine Impurities; A Failure, Challenge & Threat
Nitrosamine Impurities; A Failure, Challenge & Threat
 
Schedule M drugs and Cosmetics_Good manufacturing practices
Schedule M drugs and Cosmetics_Good manufacturing practicesSchedule M drugs and Cosmetics_Good manufacturing practices
Schedule M drugs and Cosmetics_Good manufacturing practices
 
Extractable and leachables
Extractable and leachablesExtractable and leachables
Extractable and leachables
 
History & Evolution of GMP Regulations
History & Evolution of GMP RegulationsHistory & Evolution of GMP Regulations
History & Evolution of GMP Regulations
 
Ich q3 d elemental impurities
Ich q3 d elemental impuritiesIch q3 d elemental impurities
Ich q3 d elemental impurities
 
Quality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental MonitoringQuality Risk Assessmsnt for Environmental Monitoring
Quality Risk Assessmsnt for Environmental Monitoring
 
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
Jordi Labs Agilent Extractables & Leachables (E&L) Webinar Presentation (Part...
 

Similar to Occupational exposure limits (OEL) to chemical agents APIs - Quantitative Risk Assessment

Regulatory complexities in hp drugs
Regulatory complexities in hp drugsRegulatory complexities in hp drugs
Regulatory complexities in hp drugsBhaswat Chakraborty
 
Toxicology endpoints
Toxicology endpointsToxicology endpoints
Toxicology endpoints
ArreyettaBawakAugust
 
839
839839
Alternative and integrated testing strategies
Alternative and integrated testing strategiesAlternative and integrated testing strategies
Alternative and integrated testing strategies
EFSA EU
 
Material Handling 50-53
Material Handling 50-53Material Handling 50-53
Material Handling 50-53Sadik Khan
 
Nlc Risk Assessment Training Part Ii Final
Nlc Risk Assessment Training Part Ii FinalNlc Risk Assessment Training Part Ii Final
Nlc Risk Assessment Training Part Ii FinalThanasisSShare
 
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
L3- PERMISSIBLE THRESHOLD LIMITS.pptxL3- PERMISSIBLE THRESHOLD LIMITS.pptx
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
PRACHI DESSAI
 
Toxicology_Industrial Hygiene 2021 (1).pptx
Toxicology_Industrial Hygiene 2021 (1).pptxToxicology_Industrial Hygiene 2021 (1).pptx
Toxicology_Industrial Hygiene 2021 (1).pptx
ssuser3849ae
 
PDC on Risk and Hazard Assessment, Maharshi Mehta
PDC on Risk and Hazard Assessment, Maharshi MehtaPDC on Risk and Hazard Assessment, Maharshi Mehta
PDC on Risk and Hazard Assessment, Maharshi Mehta
Kartik Vora
 
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, OccuconPDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
International Safety Systems
 
Occupational hygiene physical and biological agents
Occupational hygiene physical and biological agents Occupational hygiene physical and biological agents
Occupational hygiene physical and biological agents
Jose M. Tobar
 
Chemical Injury.pptx
Chemical Injury.pptxChemical Injury.pptx
Chemical Injury.pptx
Najads1
 
MWM Unit 3 (1).pptx
MWM Unit 3 (1).pptxMWM Unit 3 (1).pptx
MWM Unit 3 (1).pptx
ssuser1ecccc
 
Chemical hazards
 Chemical hazards Chemical hazards
Chemical hazards
Sameer Patel
 
Occupational health and toxicity
Occupational health and toxicityOccupational health and toxicity
Occupational health and toxicity
Dr. Ketna Atul Matkar
 
Cleaning validation a risk integrated approach
Cleaning validation a risk integrated approachCleaning validation a risk integrated approach
Cleaning validation a risk integrated approach
Sambhujyoti Das
 
assignment
 assignment assignment
assignment
Saumya Das Awasthi
 
Guidance for Industry and Other Stakeholders Toxicological Principles for the...
Guidance for Industry and Other StakeholdersToxicological Principles for the...Guidance for Industry and Other StakeholdersToxicological Principles for the...
Guidance for Industry and Other Stakeholders Toxicological Principles for the...
Dmitri Popov
 
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptxptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
PriyashreeK1
 
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
morosini1952
 

Similar to Occupational exposure limits (OEL) to chemical agents APIs - Quantitative Risk Assessment (20)

Regulatory complexities in hp drugs
Regulatory complexities in hp drugsRegulatory complexities in hp drugs
Regulatory complexities in hp drugs
 
Toxicology endpoints
Toxicology endpointsToxicology endpoints
Toxicology endpoints
 
839
839839
839
 
Alternative and integrated testing strategies
Alternative and integrated testing strategiesAlternative and integrated testing strategies
Alternative and integrated testing strategies
 
Material Handling 50-53
Material Handling 50-53Material Handling 50-53
Material Handling 50-53
 
Nlc Risk Assessment Training Part Ii Final
Nlc Risk Assessment Training Part Ii FinalNlc Risk Assessment Training Part Ii Final
Nlc Risk Assessment Training Part Ii Final
 
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
L3- PERMISSIBLE THRESHOLD LIMITS.pptxL3- PERMISSIBLE THRESHOLD LIMITS.pptx
L3- PERMISSIBLE THRESHOLD LIMITS.pptx
 
Toxicology_Industrial Hygiene 2021 (1).pptx
Toxicology_Industrial Hygiene 2021 (1).pptxToxicology_Industrial Hygiene 2021 (1).pptx
Toxicology_Industrial Hygiene 2021 (1).pptx
 
PDC on Risk and Hazard Assessment, Maharshi Mehta
PDC on Risk and Hazard Assessment, Maharshi MehtaPDC on Risk and Hazard Assessment, Maharshi Mehta
PDC on Risk and Hazard Assessment, Maharshi Mehta
 
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, OccuconPDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
PDC on Hazard and Risk Assessment by Maharshi Mehta, ISS, Occucon
 
Occupational hygiene physical and biological agents
Occupational hygiene physical and biological agents Occupational hygiene physical and biological agents
Occupational hygiene physical and biological agents
 
Chemical Injury.pptx
Chemical Injury.pptxChemical Injury.pptx
Chemical Injury.pptx
 
MWM Unit 3 (1).pptx
MWM Unit 3 (1).pptxMWM Unit 3 (1).pptx
MWM Unit 3 (1).pptx
 
Chemical hazards
 Chemical hazards Chemical hazards
Chemical hazards
 
Occupational health and toxicity
Occupational health and toxicityOccupational health and toxicity
Occupational health and toxicity
 
Cleaning validation a risk integrated approach
Cleaning validation a risk integrated approachCleaning validation a risk integrated approach
Cleaning validation a risk integrated approach
 
assignment
 assignment assignment
assignment
 
Guidance for Industry and Other Stakeholders Toxicological Principles for the...
Guidance for Industry and Other StakeholdersToxicological Principles for the...Guidance for Industry and Other StakeholdersToxicological Principles for the...
Guidance for Industry and Other Stakeholders Toxicological Principles for the...
 
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptxptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
ptsm2 , unit 2 ( acute dermal toxicity) By; priyashree.pptx
 
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
Choosing Chemicals for Precautionary Regulation: A Filter Series Approach (2005)
 

More from Azierta

Farmacovigilancia informe pass good vigilance practices (gvp) modulo viii
Farmacovigilancia informe pass good vigilance practices (gvp) modulo viiiFarmacovigilancia informe pass good vigilance practices (gvp) modulo viii
Farmacovigilancia informe pass good vigilance practices (gvp) modulo viii
Azierta
 
Ich q3d for elemental impurities risk evaluation
Ich q3d for elemental impurities risk evaluationIch q3d for elemental impurities risk evaluation
Ich q3d for elemental impurities risk evaluation
Azierta
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
Azierta
 
Safety reports rmp risk management plan pharmacovigilance
Safety reports rmp risk management plan pharmacovigilanceSafety reports rmp risk management plan pharmacovigilance
Safety reports rmp risk management plan pharmacovigilance
Azierta
 
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
Azierta
 
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
Azierta
 
Safety reports. addendum to the clinical overview. aco
Safety reports. addendum to the clinical overview. acoSafety reports. addendum to the clinical overview. aco
Safety reports. addendum to the clinical overview. aco
Azierta
 
Farmacovigilancia gestión y desarrollo de informes individual safety case r...
Farmacovigilancia  gestión y desarrollo de informes  individual safety case r...Farmacovigilancia  gestión y desarrollo de informes  individual safety case r...
Farmacovigilancia gestión y desarrollo de informes individual safety case r...
Azierta
 
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
Azierta
 
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IVFarmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
Azierta
 
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
Azierta
 
Casos de éxito en el desarrollo de innovadores y biosimilares
Casos de éxito en el desarrollo de innovadores y biosimilaresCasos de éxito en el desarrollo de innovadores y biosimilares
Casos de éxito en el desarrollo de innovadores y biosimilares
Azierta
 
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo IIIFarmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
Azierta
 
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
Azierta
 
Farmacovigilancia Good Vigilance Practices I Sistemas de calidad
Farmacovigilancia Good Vigilance Practices I Sistemas de calidadFarmacovigilancia Good Vigilance Practices I Sistemas de calidad
Farmacovigilancia Good Vigilance Practices I Sistemas de calidad
Azierta
 
Farmacovigilancia: Vision general de la farmacovigilancia
Farmacovigilancia: Vision general de la farmacovigilanciaFarmacovigilancia: Vision general de la farmacovigilancia
Farmacovigilancia: Vision general de la farmacovigilancia
Azierta
 

More from Azierta (16)

Farmacovigilancia informe pass good vigilance practices (gvp) modulo viii
Farmacovigilancia informe pass good vigilance practices (gvp) modulo viiiFarmacovigilancia informe pass good vigilance practices (gvp) modulo viii
Farmacovigilancia informe pass good vigilance practices (gvp) modulo viii
 
Ich q3d for elemental impurities risk evaluation
Ich q3d for elemental impurities risk evaluationIch q3d for elemental impurities risk evaluation
Ich q3d for elemental impurities risk evaluation
 
Development safety update report (dsur) pharmacovigilance and safety
Development safety update report (dsur)   pharmacovigilance and safetyDevelopment safety update report (dsur)   pharmacovigilance and safety
Development safety update report (dsur) pharmacovigilance and safety
 
Safety reports rmp risk management plan pharmacovigilance
Safety reports rmp risk management plan pharmacovigilanceSafety reports rmp risk management plan pharmacovigilance
Safety reports rmp risk management plan pharmacovigilance
 
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
Evaluacion del riesgo cuantitativo (oel) y categorizacion de la exposicion oc...
 
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
Farmacovigilancia. Informe periodico de seguridad. periodic safety update rep...
 
Safety reports. addendum to the clinical overview. aco
Safety reports. addendum to the clinical overview. acoSafety reports. addendum to the clinical overview. aco
Safety reports. addendum to the clinical overview. aco
 
Farmacovigilancia gestión y desarrollo de informes individual safety case r...
Farmacovigilancia  gestión y desarrollo de informes  individual safety case r...Farmacovigilancia  gestión y desarrollo de informes  individual safety case r...
Farmacovigilancia gestión y desarrollo de informes individual safety case r...
 
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
Farmacovigilancia. RMP. Risk Management Plan. Good Pharmacovigilance Practice...
 
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IVFarmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
Farmacovigilancia. Auditorías. Good Pharmacovigilance Practices (GVP). Módulo IV
 
Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
 
Casos de éxito en el desarrollo de innovadores y biosimilares
Casos de éxito en el desarrollo de innovadores y biosimilaresCasos de éxito en el desarrollo de innovadores y biosimilares
Casos de éxito en el desarrollo de innovadores y biosimilares
 
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo IIIFarmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
Farmacovigilancia. Inspecciones. Good Pharmacovigilance Practices: Modulo III
 
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
Farmacovigilancia. Pharmacovigilance System Master File. Good Vigilance Pract...
 
Farmacovigilancia Good Vigilance Practices I Sistemas de calidad
Farmacovigilancia Good Vigilance Practices I Sistemas de calidadFarmacovigilancia Good Vigilance Practices I Sistemas de calidad
Farmacovigilancia Good Vigilance Practices I Sistemas de calidad
 
Farmacovigilancia: Vision general de la farmacovigilancia
Farmacovigilancia: Vision general de la farmacovigilanciaFarmacovigilancia: Vision general de la farmacovigilancia
Farmacovigilancia: Vision general de la farmacovigilancia
 

Recently uploaded

Orion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWSOrion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWS
Columbia Weather Systems
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
AlaminAfendy1
 
Chapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisisChapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisis
tonzsalvador2222
 
Toxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and ArsenicToxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and Arsenic
sanjana502982
 
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
yqqaatn0
 
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
Studia Poinsotiana
 
GBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture MediaGBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture Media
Areesha Ahmad
 
extra-chromosomal-inheritance[1].pptx.pdfpdf
extra-chromosomal-inheritance[1].pptx.pdfpdfextra-chromosomal-inheritance[1].pptx.pdfpdf
extra-chromosomal-inheritance[1].pptx.pdfpdf
DiyaBiswas10
 
in vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptxin vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptx
yusufzako14
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
RenuJangid3
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
Richard Gill
 
nodule formation by alisha dewangan.pptx
nodule formation by alisha dewangan.pptxnodule formation by alisha dewangan.pptx
nodule formation by alisha dewangan.pptx
alishadewangan1
 
Hemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptxHemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptx
muralinath2
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
moosaasad1975
 
S.1 chemistry scheme term 2 for ordinary level
S.1 chemistry scheme term 2 for ordinary levelS.1 chemistry scheme term 2 for ordinary level
S.1 chemistry scheme term 2 for ordinary level
ronaldlakony0
 
Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless ReproducibilityDeep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless Reproducibility
University of Rennes, INSA Rennes, Inria/IRISA, CNRS
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Sérgio Sacani
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
YOGESH DOGRA
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
muralinath2
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
pablovgd
 

Recently uploaded (20)

Orion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWSOrion Air Quality Monitoring Systems - CWS
Orion Air Quality Monitoring Systems - CWS
 
In silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptxIn silico drugs analogue design: novobiocin analogues.pptx
In silico drugs analogue design: novobiocin analogues.pptx
 
Chapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisisChapter 12 - climate change and the energy crisis
Chapter 12 - climate change and the energy crisis
 
Toxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and ArsenicToxic effects of heavy metals : Lead and Arsenic
Toxic effects of heavy metals : Lead and Arsenic
 
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
如何办理(uvic毕业证书)维多利亚大学毕业证本科学位证书原版一模一样
 
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...
 
GBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture MediaGBSN - Microbiology (Lab 4) Culture Media
GBSN - Microbiology (Lab 4) Culture Media
 
extra-chromosomal-inheritance[1].pptx.pdfpdf
extra-chromosomal-inheritance[1].pptx.pdfpdfextra-chromosomal-inheritance[1].pptx.pdfpdf
extra-chromosomal-inheritance[1].pptx.pdfpdf
 
in vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptxin vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptx
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
 
nodule formation by alisha dewangan.pptx
nodule formation by alisha dewangan.pptxnodule formation by alisha dewangan.pptx
nodule formation by alisha dewangan.pptx
 
Hemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptxHemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptx
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
 
S.1 chemistry scheme term 2 for ordinary level
S.1 chemistry scheme term 2 for ordinary levelS.1 chemistry scheme term 2 for ordinary level
S.1 chemistry scheme term 2 for ordinary level
 
Deep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless ReproducibilityDeep Software Variability and Frictionless Reproducibility
Deep Software Variability and Frictionless Reproducibility
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
 
Mammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also FunctionsMammalian Pineal Body Structure and Also Functions
Mammalian Pineal Body Structure and Also Functions
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
 

Occupational exposure limits (OEL) to chemical agents APIs - Quantitative Risk Assessment

  • 1. QUANTITATIVE RISK ASSESSMENT AND THE CATEGORISATION OF OCCUPATIONAL EXPOSURE TO CHEMICAL AGENTS/APIs
  • 2. 1. INTRODUCTION 2. RISK ASSESSMENT 3. CATEGORIZATION 2
  • 4. INTRODUCTION The Occupational Exposure Limit (OEL) is defined as the airborne concentration of a substance (expressed as a weighted average in time for a working day of 8 hours/day and 40 hours/working week) under which it is believed that nearly all workers may be repeatedly exposed (day after day, over a working lifetime) without adverse health effects (ACGIH, 2006; DFG, 2005). Occupational exposure limits (OELs) are a useful tool to prevent adverse effects on health when managing chemical substances. On a European scale… • Employers are legally obliged to provide a work environment that does not threaten the health of the workers (Chemical Agent Directive 98/24/EC and Framework Directive 89/391/EEC). • Under Directive 89/391/EEC, OELs can be developed nationally, Indicative Occupational Exposure Limit Values (IOELVs). 4
  • 5. INTRODUCTION SOME LIMIT VALUES IN THE WORLD • TLV ®(1950): Threshold Limit Value American Conference of Governmental Industrial Hygienists (ACGIH) • REL®: Recomended Exposure Limits National Institute for Occupational Safety and Health (NIOSH) • PEL®: Permissible Exposure Limits Occupational Safety and Health Administration (OSHA) • OEL®: Occupational Exposure Limits Health and Safety Executive (HSE) • VME®: Valeurs Moyennes d´Exposition Institute National de la Recherche et la Securité (INRS) • MAK®: Maximale Arbeitsplatzkoncentrationen Deustche Forschungsgemeinschaft (DFG) GESTIS - International limit values for chemical agents 5
  • 7. RISK ASSESSMENT (ECETOC TR No. 101) What should we do if there is no regulatory OEL value? 7
  • 8. RISK ASSESSMENT(ECETOC TR No. 101) We calculate the OEL based on: • Epidemiological studies or • Toxicological data selecting the point of departure (POD) established by repeated dosage studies in animals and applying appropriate correction factors (ECETOC, 2003a) to take uncertainty and variability in the set of data into account: ➢ NOAEL no-observed-adverse-effect level and ➢ LOAEL lowest-observed-adverse-effect level 8
  • 9. RISK ASSESSMENT 9 D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
  • 10. RISK ASSESSMENT (ECETOC TR No. 101) Relevant points to establish an OEL: • Repeated dosage studies must last for at least 28 days. • Toxicokinetic studies can provide information on the extent to which the manner of exposure, distribution, metabolism and excretion of the substance in animals are adequate to establish an OEL in humans. • The criteria to select a NOAEL include the selection of the most relevant species for man. If several studies are conducted with different species, the highest NOAEL must be used, but this NOAEL must not exceed the LOAEL in any of the other studies 10
  • 11. RISK ASSESSMENT Correction factors: 11 D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
  • 13. RISK ASSESSMENT Correction factors: • UFH : A value of 10 is normally used for the general population, in the absence of specific chemical data. • UFL : 1 (POD=NOAEL), 10 (POD=LOAEL) • UFS : The purpose of OELs is to protect workers that are exposed throughout their working life, in animals this is usually compared with a chronic study (e.g. two (2) years for rats and mice). 13 D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
  • 14. RISK ASSESSMENT UFD: 1-10. Incomplete toxicological data (studies of a single species, there are no reproduction or development data, etc.) Toxicokinetic (TK) adjustment: Example: If an OEL is established from a critical effect in an oral study with a bioavailability of 10%, bearing in mind that bioavailability for inhalation is 100%: 1.0/0.1 or a factor of 10. Modification factor (MF): This factor is adjusted for uncertainties not tackled by the UFs described above (<1 to 10). 14 D. A. Dankovic, B. D. Naumann et al. The Scientific Basis of Uncertainty Factors Used in Setting Occupational Exposure Limits. J Occup Environ Hyg. 2015 Nov 25; 12(sup1): S55–S68.
  • 15. RISK ASSESSMENT (ECETOC TR No. 101) If there is no NOAEL/LOAEL: • The maximum tolerated dose in long term studies can be used to establish an OEL. If this is not known, the maximum tolerated dose can be predicted based on acute oral toxicity (lethal dose in rats) and the octanol-water distribution coefficient. Molecules with a molecular mass of <500 and a Kow log of 0–4 are absorbed well orally or by inhalation. • Lethal concentrations of four hours of inhalation studies in rats can be directly used to calculate the OEL. 15
  • 16. RISK ASSESSMENT (ECETOC TR No. 101) If there is no NOAEL/LOAEL: • The use of QSARs to predict the toxicity is not reliable enough, therefore, they are of limited value when it comes to establishing the OEL. It is better to look for substances with similar structures and known toxicity (Read-across). ChemIDplus (http://chem.sis.nlm.nih.gov/chemidplus/) (NLM, 2004). • You can resort to the Threshold of Toxicological Concern (TTC), which is normally used for food contaminants to determine the OEL by the most conservative method. The first step in applying the TTC concept for a particular substance is to identify the possible genotoxic effects and/or highly potent carcinogens. If estimated intake does not exceed 1.5 μg / person / day, you would not expect the substance to be a safety problem. 16
  • 17. RISK ASSESSMENT (ECETOC TR No. 101) At present, there are no procedures to establish the OELs for data-poor substances. Data poor substances: Substances that fall under Annex V of REACH (volume of up to 10 t/year) form part of this category. One possibility could be to use the derived-no-effect level (DNEL), taking this as an OEL equivalent. 17
  • 18. 18 Considerations to be taken into account: • The absorption of a chemical substance is conditioned by: ➢ Physical state: Gas (inhalation), liquid (vapour inhalation, aerosol droplets, directly through the skin), solid (aerosol inhalation) ➢ Temperature: When handling, during shipment, storage, etc. ➢ Dust of any type can become a hazardous substance when it is present in airborne concentrations equal to or over 10 mg / m3 of inhalable dust or 4 mg / m3 of respirable dust. RISK ASSESSMENT (ECETOC TR No. 101)
  • 19. 19 Considerations to be taken into account: ✓ The substance can also cause harm when: • being absorbed through the skin; • being ingested; or • acting directly on the body at the point of contact, e.g. the skin. RISK ASSESSMENT (ECETOC TR No. 101)
  • 20. 20 RESPIRATORY/SKIN/EYE IRRITANT AGENT Because of its limited solubility in water, the substance may reach: • The alveoli or • Be inhaled as critically-sized particles ("respirable dust"), The OEL must be based on the prevention of: ➢ Damage to the lung epithelium in the short term ➢ COPD, emphysema or pulmonary fibrosis after long-term exposure. Contact with the skin can cause irritation and contact dermatitis. If a substance has a high octanol-water partition coefficient and a low skin DL50, e.g. 1000 mg / kg, the possibility of skin irritation must be considered. RISK ASSESSMENT
  • 21. 21 RESPIRATORY SENSITISER AGENT A substance is considered to cause occupational asthma if, on account of exposure in the workplace: ➢ It provokes a biological change known as a “hypersensitive state” in the respiratory tracts; and ➢ It provokes a subsequent reaction in those respiratory tracts. • Substances may not be hazardous in solid form but may indeed by so in fine powder or dust form which can be inhaled into the lungs. • Nanoparticles (<100 nanometres) can be more toxic than bigger ones of the same substance. • Impurities in a substance can make it more dangerous. RISK ASSESSMENT
  • 22. 22 SKIN SENSITISER AGENT Allergic skin contact: Repeated exposure to a relatively low concentration. There is a class of chemical substances that can cause allergic reactions in the skin after exposure to sunlight or ultraviolet (UV) light. These chemical products are known as photosensitisers. Penetration of the skin can increase in highly humid settings. When temperatures are high, perspiration can contribute to greater skin absorption. RISK ASSESSMENT
  • 23. 23 An adjusted OEL (AOEL) can be calculated when worker exposure time is not 8 hours a day RISK ASSESSMENT- AOELs
  • 24. How is the OEL calculated in compounds? Three possible compound cases are considered: Synergistic substances: Quite uncommon. These are the most serious cases. Additive substances: when there are reasons to believe that the effect of the components are additive and are based on the same effects on health. Independent substances: when the synergistic or additive effects are not known or considered unlikely, the constituents can be considered as working independently and the requisite measures are analysed to attain adequate control separately. 24 RISK ASSESSMENT- COMPOUNDS (ECETOC TR No. 101)
  • 25. 25 ➢ If the total is < 1, exposure to the compound is below the OEL value ➢ If the total is > 1, exposure to the compound is above the OEL value RISK ASSESSMENT- COMPOUNDS (ECETOC TR No. 101) Additive:
  • 26. 26 RISK ASSESSMENT- COMPOUNDS (ECETOC TR No. 101)
  • 27. 27 ✓ Toxicology databases for the work environment ✓ Buscatox ✓ QSAR/READ-ACROSS ✓ Danish QSAR ✓ Toxtree ✓ Vega RISK ASSESSMENT- DATA BASE
  • 29. CATEGORIZATION SYSTEMS Naumann et al., 1996: • system based on five (5) categories • range of permissible occupational exposure limits (PEL) that range from 1000 - 5000 μg/m3 in category 1 to those values under 100 ng/m3 in category 5. Safebridge (SB) proposes, as does the ISPE • a system based on four (4) categories • a broader band range than in the previous case. INSHT (NTP 798) System based on five (5) categories 29
  • 30. CATEGORIZATION SYSTEMS - AZIERTA 30 See the table in www.azierta.eu Once the OEL value has been calculated and the toxicological analysis of the substance carried out, a categorization of the substance shall be carried out taking into account the toxicological and pharmacological characteristics as well as the physicochemical properties of the substance.
  • 31. In Azierta we are experts in Exposure Limits, Categorization of APIs and Protocols of Health Surveillance if you want to know us visit: Azierta Or follow us on : Azierta @Azierta